Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision?

Archive ouverte

Aldea, M. | Friboulet, L. | Apcher, S. | Jaulin, F. | Mosele, F. | Sourisseau, T. | Soria, J.-C. | Nikolaev, S. | André, F.

Edité par CCSD ; European Society for Medical Oncology -

International audience. Precision medicine for cancer is rapidly moving to an approach that integrates multiple dimensions of the biology in order to model mechanisms of cancer progression in each patient. The discovery of multiple drivers per tumor challenges medical decision that faces several treatment options. Drug sensitivity depends on the actionability of the target, its clonal or subclonal origin and coexisting genomic alterations. Sequencing has revealed a large diversity of drivers emerging at treatment failure, which are potential targets for clinical trials or drug repurposing. To effectively prioritize therapies, it is essential to rank genomic alterations based on their proven actionability. Moving beyond primary drivers, the future of precision medicine necessitates acknowledging the intricate spatial and temporal heterogeneity inherent in cancer. The advent of abundant complex biological data will make artificial intelligence algorithms indispensable for thorough analysis. Here, we will discuss the advancements brought by the use of high-throughput genomics, the advantages and limitations of precision medicine studies and future perspectives in this field.

Consulter en ligne

Suggestions

Du même auteur

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Archive ouverte | Mosele, F. | CCSD

International audience

Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients

Archive ouverte | Chen, J. | CCSD

International audience. Background: The development of targeted agents, such as osimertinib for EGFR-mutated non-small-cell lung cancer (NSCLC), has drastically improved patient outcome, but tumor resistance eventua...

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

Archive ouverte | Bayle, A. | CCSD

International audience

Chargement des enrichissements...